Back to Journals HIV/AIDS - Research and Palliative Care Volume 7 L-carnitine supplementation in patients with HIV/AIDS and fatigue: a double-blind, placebo-controlled pilot study Authors Cruciani R, Revuelta M, Dvorkin E, Homel P, Lesage P, Esteban-Cruciani N Received 23 April 2014 Accepted for publication 11 July 2014 Published 19 February 2015 Volume 2015:7 Pages 6573 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Ricardo A Cruciani, 1 Manuel Revuelta, 2 Ella Dvorkin, 3 Peter Homel, 4 Pauline Lesage, 5 Nora Esteban-Cruciani 6 1 Center for Comprehensive Pain Management and Palliative Care, Capital Institute for Neurosciences, Capital Health Medical Center, Pennington, NJ, 2 Lee Memorial Hospital, Fort Myers, FL, 3 Institutional Review Board, New York University, New York, NY, 4 Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY, 5 Maimonides Medical Center, Brooklyn, NY, 6 Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA Background: The purpose of this study was to determine the effect of L-carnitine supplementation on fatigue in patients with terminal human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS)

This is the first time Ive left a review (ever)
It promotes the production of growth factors and extracellular matrix proteins, which are essential for skin regeneration and collagen formation
Meanwhile, the percentage of Americans who have been diagnosed with diabetes a lifetime disease that can be managed but not cured has remained steady since 2023 after 15 years of slowly rising rates concurring with rising obesity
Tort F et al (2014) Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2-ketoacid dehydrogenase complexes
Conjunctival primary acquired melanosis can be precancerous and early detection is critical